• My Basket 0

    Badrilla Default welcome msg!

    PLN Degradation

    PLN Degradation

    Metformin increases degradation of phospholamban via autophagy

    David Maclennan's group in Toronto have studied PLN stability and degradation in primary cultured mouse neonatal cardiomyocytes (CMNCs) and mouse hearts. Read the full paper here. Discover other publications from the Maclennan group here.

    Key findings to date:

    • Inhibition of lysosomal and autophagic activities promotes endogenous PLN accumulation, whereas;
    • Acceleration of autophagy with autophagy activator metformin enhances PLN degradation in CMNCs.
    • Pentameric PLN is polyubiquitinylated at the K3 residue
    • Ubiquitinylation is required for p62-mediated selective autophagy trafficking
    • Identifies a mechanism that traffics PLN to the lysosomes for degradation

    Which tools do I need? Badrilla is pleased to offer new panel of reagents to facilitate the study of ubiquitination and autophagy in your experimental workflow.

    2 Item(s)

    1. Bafilomycin A1

      Product code: A010-502

      Highly potent, selective inhibitor of vacuolar type H+-ATPase (V-ATPase). Selective for V-ATPase over other ATP hydrolyzing enzymes

      Learn More
    2. AccuMarQ Pre-stained Molecular Weight Markers

      Product code: A010-601

      AccuMarQ pre-stained molecular weight markers represent a set of 12 multi-coloured protein standards covering a broad range of molecular weights (10 to 245 kDa).

      Learn More

    2 Item(s)

    Shop By

    Currently Shopping by:

    1. Target: V-ATPase Remove This Item
    Product type
    1. Inhibitor (2)

    You have no items to compare.

    Contact Us

    Leeds Innovation Centre

    103 Clarendon Road

    Leeds LS2 9DF

    United Kingdom

    +44 (0)7801 730618


    Useful Links


    DISCLAIMER: Products for research use only (RUO) and are not intended for diagnostic or therapeutic use.

    Badrilla Newsletters

    Sign up for Badrilla newsletters today and receive twice-monthly informative emails relating to cardiovascular research.
    Badrilla enewsletter sign up